Anxiety & Stress Disorders

Effective diagnosis and treatment of comorbid disorders in patients with bipolar enhance care and lead to more optimal mental health outcomes.

What is the hidden mental health struggles of affluent youth? In this Tales From the Clinic article, we reveal how wealth can contribute to anxiety, depression, and substance misuse.

Check out the pipeline updates from April!

In this CME article, explore the complexities of Parkinson disease, focusing on neuropsychiatric symptoms, their prevalence, and effective treatment strategies for improved patient care.

Cybin partners with Osmind to enhance mental health treatment access, focusing on innovative therapies for depression and anxiety disorders.

The first patient has been dosed in MindMed’s phase 3 Emerge study evaluating the efficacy of MM120 ODT.

A pioneer in cognitive behavior therapy shares his thoughts on a 50-year-long career.

New research reveals that discontinuing long-term benzodiazepine therapy may increase risks of mortality and other adverse outcomes, challenging common assumptions.

Are TV shows educating the public about psychiatric medications?

What is the difference between worry and anxiety disorders?

Epidemiological data show that rates of anxiety, depression, self-injurious behaviors, and suicidality increased for Gen Z in significantly higher numbers than previous generations.

Learn more about the latest research on the impact the endocrine system has on major depressive disorder.

In mice models, opioid delta-receptor agonists showed promise in helping to relieve abdominal pain and regulate bowel movements. Is targeting the brain the best path forward for IBS treatment?

Meditation using immersive virtual reality devices can help alleviate symptoms of major depressive disorder and generalized anxiety disorder.

How does affluence impact mental health outcomes?

Clinicians should consider rTMS as an intervention to alleviate OCD symptoms, especially in those who have failed other treatments or those with comorbid depression.

With MM120 in phase 3 in the MindMed trial, what place do psychedelics hold in psychiatry?

MindMed announced phase 3 study of psychedelic MM120 for Generalized Anxiety Disorder.

MindMed announced phase 3 of a trial testing a new treatment for generalized anxiety disorder is under way.

Let's look back on a year marked by advancements and ongoing challenges in psychiatry.

Here are 4 means of coping with the diagnostic uncertainty of bipolar mixed states.

The FDA has granted clearance to the Horizon Inspire transcranial magnetic stimulation system to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression.

How can you distinguish bipolar mixed states? Stay tuned in this short series.

It’s time to address adult ADHD.

A new study shows that rTMS has moderate therapeutic effects on OCD severity.

Recent research has highlighted important functional aspects of vitamin D. Learn more here.

There is still no formal or professional recognition of complex PTSD as a very different disorder than what DSM-5-TR describes for PTSD.

Is the complex posttraumatic stress disorder diagnosis being used to avoid the diagnosis of borderline personality disorder?

DaylightRx becomes the very first FDA-cleared digital treatment for generalized anxiety disorder.

While new treatment options in the PTSD space can be exciting, we cannot lose sight of the treatments that are already readily available.